老年患者牛皮的系统生物治疗方法
Sapir Glazer Levavi1, Ronny Maman2, Shany Sherman1,2
1Division of Dermatology, Rabin Medical Center, Beilinson Hospital, Petach Tikva 49100, Israel.
Journal of clinical medicine
|July 12, 2025
概括
在老年患者治疗牛皮时,生物药物是有效和安全的. 一些治疗方法,如阿达利穆马布和古塞尔库马布,在65岁后开始时,药物生存率更好.
科学领域:
- 皮肤病学 皮肤病学
- 老年医学 老年医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 牛皮会影响60岁以上的显著比例的人.
- 老年患者经常被排除在临床试验之外,这限制了这一群体对生物疗效和安全的数据.
研究的目的:
- 评估生物药物治疗老年牛皮的疗效和安全性.
- 为了比较65岁之前和65岁之后开始生物治疗的患者之间的结果.
主要方法:
- 追溯队列研究涉及149名老年牛皮患者.
- 患者被分为两组:65岁以下 (成人开始) 和65岁以上 (老年开始).
- 分析包括患者特征,药物存活率和安全结果 (因感染入院,死亡).
主要成果:
- 群体之间的人口统计,并发症和治疗周转率是可比的.
- 在老年人开始组中,阿达利穆马布 (一线) 和古塞尔库马布 (任意序列) 显示药物存活率明显更好.
- 两组之间没有观察到药物安全性的显著差异,包括因感染或死亡而住院的情况.
结论:
- 生物疗法在老年人群中治疗牛皮既有效又安全.
- 某些生物药物,特别是阿达利穆马布和古塞尔库马布,在65岁以上的患者开始使用时,可能会改善药物存活率.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
237
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
237
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
272
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
272
Inflammatory Bowel Disease IV: Pharmacological Management
198
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
198
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
204
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
204
Nephrotic Syndrome III : Nursing Management
48
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
48
Nephrotic Syndrome II : Assessment and Medical Management
23
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
23


